Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano Holdings, Inc. was incorporated in 1996 and is headquartered in Minato, Japan.
Metrics to compare | 4571 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4571PeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.1x | −5.2x | −0.6x | |
PEG Ratio | −1.70 | 0.02 | 0.00 | |
Price/Book | 4.0x | 3.3x | 2.6x | |
Price / LTM Sales | 75.1x | 28.5x | 3.4x | |
Upside (Analyst Target) | - | 48.8% | 40.5% | |
Fair Value Upside | Unlock | 5.3% | 4.4% | Unlock |